The degree to which the PCA3 test is a useful tool in assessment of risk for clinically significant prostate cancer prior to biopsy has never, really, been entirely clear. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: Diagnosis, mltiparametric, mpMRI, MRI, PCA3, risk | 2 Comments »
The prostate cancer antigen 3 or PCA3 test was initially approved as an aid to the assessment of risk of prostate cancer in men with an elevated PSA level who had already been given at least one prior, negative biopsy. … READ MORE ..
Filed under: Diagnosis, Risk | Tagged: accuracy, Diagnosis, PCA3, risk, sensitivity | Leave a comment »
The National Institute for Health and Care Excellence (NICE) has issued draft guidance stating that two approved tests for risk of prostate cancer are not clinically useful in England. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: Diagnosis, PCA3, phi, Prostate Health Index, risk | 4 Comments »
We now have five approved tests that can (at least in theory) help a man — and his doctors — to decide whether he is at sufficient risk for clinically significant prostate cancer that he should go get a biopsy. But how good are they really? … READ MORE …
Filed under: Diagnosis, Risk | Tagged: 4Kscore, free, MRI, multi-parametric, PCA3, phi, PSA | 5 Comments »
Some studies (e.g., this one by Roobol et al.) have previously indicated that not all men with very high prostate cancer antigen 3 (PCA3) scores are necessarily found to have prostate cancer on biopsy or re-biopsy. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: biopsy, Diagnosis, PCA3, re-biopsy, risk, test | 6 Comments »
Regular readers will be aware that a PSA density (i.e., PSA ÷ prostate volume) > 0.15 has been identified and characterized as a risk factor for clinically significant prostate cancer by researchers at Johns Hopkins. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: density, Diagnosis, PCA3, risk | 4 Comments »
A new study just published on line in Clinical Cancer Research shows a degree of correlation between the results of tests for PCA3 and the TMRPSS2-ERG biomarker and risk for progressive disease in men on active surveillance. However, this correlation appears to be less than compelling. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: acgtive surveillance, biomarker, PCA3, risk, TMRPSS2-ERG | Leave a comment »
The prostate cancer gene 3 or PCA3 test has been approved exclusively as a means to assess the potential value of a repeat biopsy for a man who has already had a negative biopsy but whose PSA values (and/or other indicators) continue to suggest significant risk for prostate cancer. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: accuracy, outcome, PCA3, value | 13 Comments »
According to a report today on Xconomy.com, the U.S. Food & Drug Administration has approved the Progensa® PCA3 test developed by Gen-Probe. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: biopsy, Diagnosis, PCA3, risk, test | 4 Comments »
The possibility of approval of the Progensa® PCA3 test here in the USA any time soon appears to have received a setback. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: Gen-Probe, PCA3, Progensa | Leave a comment »
Apparently Health Canada has approved coverage of the use of Gen-Probe’s PCA3 test (Progensa™) as a diagnostic test ” to verify the need for repeat biopsies in men at risk of getting prostate cancer.” … READ MORE …
Filed under: Diagnosis, Risk | Tagged: Gen-Probe, PCA3, Progensa | Leave a comment »
There is a lot of media coverage from late yesterday about a “new” urine test for diagnosis of prostate cancer that is being developed by the University of Michigan in combination with San Diego-based Gen-Probe. Whether the actual value of the test can live up to the media coverage is going to take a while to determine. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: biopsy, PCA3, risk, test, TMPRSS2:ERG | 1 Comment »
A new study has suggested that a clinical algorithm that combines data on serum PSA with detection of TMPRSS2:ERG fusion and prostate cancer gene 3 (PCA3) in urine collected after a digital rectal exam (DRE) can predict prostate cancer on subsequent biopsy better than any one of the three potential markers alone. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: algorithm, biopsy, PCA3, PSA, risk, TMPRSS2:ERG | Leave a comment »
The prostate cancer gene 3 or PCA3 test has been commercially approved in Europe as a test that provides relevant information associated with the need for a prostate biopsy. It is still awaiting approval in the USA. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: biopsy, Diagnosis, PCA3, risk | Leave a comment »
A new study has suggested that, although the PCA3 test is slightly better than the total PSA test in prediction of risk for a positive biopsy finding, it is not necessarily always better than the free PSA test. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: biopsy, free, PCA3, positive, PSA, risk, total | 1 Comment »
THE "NEW" PROSTATE CANCER INFOLINK 